TAK

Takeda Pharmaceutical Stock Analysis

AI Rating

Neutral
  • Quality6/10
  • Growth 2/10
  • Value 5/10
Takeda Pharmaceutical sales and earnings growth
TAK Growth
Fair
  • Revenue Y/Y -2.50%
  • EPS Y/Y -45.36%
  • FCF Y/Y 14.58%
Takeda Pharmaceutical gross and profit margin trends
TAK Profitability
Neutral
  • Gross margin 65.30%
  • EPS margin 2.50%
  • ROIC 5Y 5.44%
Takeda Pharmaceutical recent dividend growth
TAK Dividends
  • Dividend yield 3.53%
  • Growth 3Y 2.51%
  • Payout ratio 2%
Takeda Pharmaceutical net debt vs free cash flow
TAK Risk
Great
  • Debt / Equity 0.7
  • Debt / FCF 5.0
  • Interest coverage 1.6

Takeda Pharmaceutical stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Drug Manufacturers - Specialty & Generic stocks ↗